270,262 Shares in Certara, Inc. $CERT Acquired by Nuveen LLC

Key Points

• Nuveen LLC has acquired a new position in Certara, Inc., purchasing 270,262 shares valued at approximately $2.68 million, representing 0.17% of the company's stock.
• Institutional investors now own 73.96% of Certara's stock, with several funds recently increasing their stakes in the company.
• Analysts have mixed ratings for Certara, with a consensus rating of "Moderate Buy" and a price target of $15.14, although the company recently missed earnings expectations for the quarter.

Nuveen LLC acquired a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 270,262 shares of the company's stock, valued at approximately $2,676,000. Nuveen LLC owned approximately 0.17% of Certara at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc raised its holdings in shares of Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after acquiring an additional 1,866 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares during the last quarter. Associated Banc Corp acquired a new stake in shares of Certara in the 1st quarter worth about $101,000. Portside Wealth Group LLC acquired a new stake in shares of Certara in the 1st quarter worth about $104,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Certara in the 1st quarter worth about $120,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Stock Down 1.5%

NASDAQ:CERT traded down $0.16 on Wednesday, hitting $10.50. The stock had a trading volume of 1,172,020 shares, compared to its average volume of 1,232,055. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16. The stock has a market cap of $1.69 billion, a P/E ratio of 210.04 and a beta of 1.43. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $15.69. The firm's fifty day simple moving average is $10.83 and its two-hundred day simple moving average is $11.41.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $104.57 million during the quarter, compared to analysts' expectations of $104.14 million. Certara had a net margin of 1.97% and a return on equity of 5.11%. The company's quarterly revenue was up 12.1% on a year-over-year basis. During the same quarter last year, the business posted $0.07 EPS. Analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CERT shares. JMP Securities restated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. UBS Group lowered their target price on shares of Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. KeyCorp lowered their target price on shares of Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Morgan Stanley started coverage on shares of Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. Finally, Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Certara has an average rating of "Moderate Buy" and an average price target of $15.14.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.